DBV Technologies (NASDAQ:DBVT) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note issued to investors on Monday. The firm issued a hold rating on the stock.

Separately, JMP Securities reaffirmed a “market outperform” rating and set a $10.00 target price on shares of DBV Technologies in a research report on Friday, January 10th.

DBV Technologies Stock Performance

DBVT stock opened at $7.44 on Monday. The company has a market capitalization of $153.03 million, a P/E ratio of -1.65 and a beta of -0.08. The company has a fifty day moving average price of $4.76 and a 200-day moving average price of $4.00. DBV Technologies has a 52-week low of $2.20 and a 52-week high of $8.50.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC acquired a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned 0.24% of DBV Technologies as of its most recent SEC filing. Institutional investors and hedge funds own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.